GlycoNex, Inc. engages in the anti-cancer monoclonal antibody development. It specializes in glycosphingolipid antigen production and identification, monoclonal antibody production, cancer drug screening, stable cell line production for monoclonal antibody, and pharmacology and pharmacokinetics assessment. The company was founded by Tong Hsuan Chang on February 1, 2001 and is headquartered in New Taipei, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company